MeCP2 Lentiviral Activation Particles (h): sc-401228-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- MeCP2 Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- MeCP2 Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by MeCP2 Lentiviral Activation Plasmid (h) and MeCP2 Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the MECP2 promoter. One or both designs may be available
- Following transfection, gene activation efficiency can be assayed by WB, IF or IHC using antibody: MeCP2 Antibody (G-6): sc-137070
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MeCP2 Lentiviral Activation Particles (h) | sc-401228-LAC | 200 µl | $455.00 |
MECP2 encodes methyl-CpG binding protein 2 (MeCP2), a chromatin-associated regulator that binds methylated DNA and shapes transcriptional programs by coordinating epigenetic repression and activation. MeCP2 influences neuronal differentiation, synaptic maturation, and activity-dependent gene expression through interactions with corepressor complexes and chromatin remodeling pathways. Perturbation of MECP2 dosage is tightly linked to neurodevelopmental and cognitive phenotypes, making it a key node for studying DNA methylation–dependent regulation and neuronal homeostasis. In human cellular models, MECP2 provides a tractable entry point to dissect transcriptional control, chromatin state dynamics, and downstream pathway responses in the nervous system.
MeCP2 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient MECP2 upregulation across a broader range of human cell types.
MeCP2 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the MECP2 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous MeCP2 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native MECP2 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.